SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

SK Bioscience and global pharmaceutical giant Sanofi signed an expanded agreement to jointly develop next-generation ...

SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting ...

SK bioscience and Sanofi, a global healthcare company, extended their partnership to co-develop next-generation pneumococcal ...

Pneumococcal conjugate vaccines (PCVs) are known to provide protection against vaccine serotype pneumococcal pneumonia; uncertainty exists regarding the optimum PCV dosing schedule. Methods ...

Throughout history, immunisation has helped protect millions of children against infectious and life-threatening diseases. Immunisation helps to strengthen your child’s immune system to fight diseases ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

This vaccine candidate is the first-ever PCV containing more than 20 serotypes to enter a phase 3 clinical study in infants and toddlers. Thomas Triomphe Executive Vice President, Vaccines, Sanofi ...

Goldman Sachs rates Vaxcyte a buy with $135 price target, highlighting vaccine platform and pneumonia candidate. Read more ...

Prioritizing disease prevention naturally requires implementing effective immunization campaigns while also fostering an ...

证券之星消息，截至2024年12月19日收盘，民生健康(301507)报收于13.52元，上涨0.3%，换手率4.21%，成交量4.65万手，成交额6219.95万元。